US Patent Issued to Memorial Sloan Kettering Cancer Center on Nov. 11 for "Anti-MUC16 antibodies and uses thereof" (American, Spanish Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,466,894, issued on Nov. 11, was assigned to Memorial Sloan Kettering Cancer Center (New York).

"Anti-MUC16 antibodies and uses thereof" was invented by David Spriggs (New York), Alberto Fernandez-Tejada (Logrono, Spain) and Dharmarao Thapi (Bayside Hills, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer."

The patent was filed on July 14, 2021, under Application No. 17/375,048.

*For further ...